Hepatocellular Carcinoma

Intratumoral Gene Therapy Delivery Best Approach In Primary Liver Cancer

Published in Gene Therapy Weekly, October 18th, 2001

by Sonia Nichols, senior medical writer - The best way to administer gene therapies targeting hepatocellular carcinoma, a primary form of liver cancer, may be directly to the tumor, the results of a new study indicate.

There seem to be too many barriers to effective intravenous gene therapy administration, according to S.K. Yoon, a researcher at Harvard Medical School in Boston Massachusetts. Yoon, collaborating in a multicenter study, hoped to gain a better understanding of the nature of gene therapy delivery in hepatocellular carcinoma (HCC). Gene therapy could potentially benefit thousands of people who develop primary liver cancers because of hepatitis viruses,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry